Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tularik
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed diagnosis of ovarian cancer
Subjects must have received 1-2 regimens of prior chemotherapy (with one containing paclitaxel)
At least 18 years of age
Bidimensionally measurable disease amenable to CT scanning. At least one lesion must be least 1 X 1 cm in size.
Karnofsky performance status of at least 70%
Estimated life expectancy of at least 12 weeks
Females of childbearing potential must have a negative pregnancy test and agree to use an effective contraceptive
Subject must be able to comply with study procedures and follow-up examinations.
Signed written informed consent
Lab Values (obtained ≤ 7 days prior to study enrollment):
ANC at least 1.5x10e9/L,
Platelet count at least 100x10e9/L,
Hemoglobin at least 8.5 g/dL,
Creatinine within 2 times upper limit of normal
AST and ALT within 3 times upper limit of normal
Bilirubin within 1.5 times upper limit of normal
Albumin great than 2.5 g/dL
INR \< 1.5 for subjects without anticoagulants
You may not be if
Severe, concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the subject inappropriate for enrollment
NYHA Class III/IV cardiac disease, left ventricular ejection fraction (LVEF) of \<50%, or acute anginal symptoms
Patients who have received any investigational agent within 4 weeks of enrollment
Patients who are pregnant or breast-feeding
History of prior malignancy other than ovarian cancer within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
History of central nervous system metastases or carcinomatous meningitis
